Texas hedge fund manager Kyle Bass has sought another inter partes review (IPR), this time to challenge a patent covering Pharmacyclics’ cancer drug Imbruvica (ibrutinib).
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Kyle Bass, Coalition for Affordable Drugs, inter partes review, Pharmacyclics, Imbruvica